Date: 2012-03-02
Type of information: Production agreement
Compound: oligonucleotide peptide conjugates
Company: Bachem (Switzerland) BioSpring (Germany)
Therapeutic area:
Type agreement: R&D
manufacturing
production
Action mechanism:
Disease:
Details: Bachem and BioSpring have agreed to collaborate on oligonucleotide peptide conjugates for R&D on the manufacture of oligonucleotide-peptide conjugates involved in R&D projects. The required expertise for both oligonucleotide and peptide chemistry are thus brought together for a future collaboration by two manufacturers experienced in their fields.
Financial terms:
Latest news:
Is general: Yes